Internal Medicine · Sacramento, CA
NPI
1568638625
Since 2008
Specialty
Internal Medicine
Code 390200000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
4150 V St # 3116
Sacramento, CA, 95817
Phone (916) 734-7087
Groups this clinician bills Medicare through
Medicare paid
-
No Medicare services published
Medicare patients
-
Drug cost, 2024
$554K
1,493 prescriptions
Company payments, 2024
$0
From 1 companies
Medicare prescription drug claims, 2024
In 2024, the drug Sarah J Perez prescribed most often to Medicare patients was Anastrozole, with 756 prescriptions and refills. In total Sarah J Perez wrote 1,493 Medicare prescriptions that cost $554K.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-02-11.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Anastrozole Generic | 756 | 2,264 | 258 | $21K |
| Exemestane Generic | 107 | 310 | 39 | $8,387 |
| Alendronate Sodium Generic | 75 | 204 | 25 | $729 |
| Tamoxifen Citrate Generic | 65 | 205 | 29 | $1,668 |
| Letrozole Generic | 61 | 184 | 23 | $1,252 |
| Dexamethasone Generic | 51 | 53 | 26 | $612 |
| Prochlorperazine Maleate Generic | 37 | 37 | 21 | $463 |
| Nivestym Filgrastim-Aafi | 36 | 36 | 13 | $27K |
| Lorazepam Generic | 34 | 34 | 11 | $327 |
| Oxycodone Hcl Generic | 26 | 26 | Under 11 | $457 |
| Ibrance Palbociclib | 25 | 25 | Under 11 | $387K |
| Ondansetron Hcl Generic | 25 | 25 | 18 | $200 |
| Granix Tbo-Filgrastim | 17 | 17 | Under 11 | $6,597 |
| Lidocaine-Prilocaine Lidocaine/Prilocaine | 16 | 20 | 15 | $598 |
| Famotidine Generic | 13 | 13 | 11 | $99.97 |
Brand drugs: 94 claims; generic drugs: 1,399 claims; opioid claims: 47.
Money and other things of value reported by the companies
In 2024, drug and medical device companies paid Sarah J Perez $0 (- in general payments such as food, travel and fees) from 1 company.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.